Continuous subcutaneous infusion of AC2993 (synthetic exendin-4) provides sustained day-long glycemic control in patients with Type 2 diabetes

被引：0
|
作者：
Taylor, K [1 ]
Kim, D [1 ]
Bicsak, T [1 ]
Heintz, S [1 ]
Varns, A [1 ]
Aisporna, M [1 ]
Fineman, M [1 ]
Baron, A [1 ]
机构：
[1] Amylin Pharmaceut Inc, San Diego, CA USA
来源：
DIABETOLOGIA | 2002年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
123
引用
收藏
页码：A43 / A44
页数：2
相关论文
共 50 条
  • [31] Continuous subcutaneous insulin infusion improves glycemic control and quality of life in type 1 diabetes patients with long standing poor glycemic control. A randomized trial
    Devries, JH
    Snoek, FJ
    Kostense, PJ
    Masurel, N
    Heine, RJ
    DIABETES, 2002, 51 : A129 - A129
  • [32] Sustained release of exendin-4 from tannic acid/Fe (III) nanoparticles prolongs blood glycemic control in a mouse model of type II diabetes
    He, Zhiyu
    Hu, Yizong
    Gui, Zaizhi
    Zhou, Yang
    Nie, Tianqi
    Zhu, Jinchang
    Liu, Zhijia
    Chen, Kuntao
    Liu, Lixin
    Leong, Kam W.
    Cao, Peng
    Chen, Yongming
    Mao, Hai-Quan
    JOURNAL OF CONTROLLED RELEASE, 2019, 301 : 119 - 128
  • [33] Influence of Glycemic Control and Variability on Diabetic Retinopathy in Type 1 Diabetes Patients on Continuous Subcutaneous Insulin Infusion Therapy
    Lecumberri, Edurne
    Bengoa, Nuria
    Fernandez Argueso, Maria
    Nattero Chavez, Lia
    DIABETES, 2020, 69
  • [34] Continuous Subcutaneous Insulin Infusion in Patients with Type 2 Diabetes Safely Improved Glycemic Control Using a Simple Insulin Dosing Regimen
    Edelman, Steve V.
    Bode, Bruce W.
    Bailey, Timothy S.
    Kipnes, Mark S.
    Frias, Juan P.
    DIABETES, 2009, 58 : A113 - A113
  • [35] Influential factors affecting glycemic control in type I diabetes patients on continuous subcutaneous insulin infusion (CSII) therapy
    Rembert, J
    Elchoufi, L
    Lilavivat, U
    DIABETES, 1999, 48 : A354 - A354
  • [36] A Randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control
    DeVries, JH
    Snoek, FJ
    Kostense, PJ
    Masurel, N
    Heine, RJ
    DIABETES CARE, 2002, 25 (11) : 2074 - 2080
  • [37] Insulin Requirement Profiles of Patients with Type 2 Diabetes After Achieving Stabilized Glycemic Control with Short-Term Continuous Subcutaneous Insulin Infusion
    Noh, Yun-Hee
    Lee, Won-Jin
    Kim, Kyoung-Ah
    Lim, Inja
    Lee, Jun-Ho
    Lee, Ju-Han
    Kim, Seonguk
    Choi, Soo-Bong
    DIABETES TECHNOLOGY & THERAPEUTICS, 2010, 12 (04) : 271 - 281
  • [38] Effect of carbohydrate counting using bolus calculators on glycemic control in type 1 diabetes patients during continuous subcutaneous insulin infusion
    Yamada, Eijiro
    Okada, Shuichi
    Nakajima, Yasuyo
    Bastie, Claire C.
    Tagaya, Yuko
    Osaki, Aya
    Shimoda, Yoko
    Shibusawa, Ryo
    Saito, Tsugumichi
    Ozawa, Atsushi
    Yamada, Masanobu
    JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (04) : 496 - 500
  • [39] Glycemic Control in Adult Type 1 Diabetes Patients with Insulin Glargine, Insulin Detemir, or Continuous Subcutaneous Insulin Infusion in Daily Practice
    Rautiainen, Paivi
    Tirkkonen, Hilkka
    Laatikainen, Tiina
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (05) : 363 - 369
  • [40] Glycemic Control in a Large Cohort of Patients with Type 1 Diabetes (T1DM) Treated with Continuous Subcutaneous Insulin Infusion (CSII)
    Leelarathna, Lalantha
    Chapman, Alyson
    Morris, Juliet
    Urwin, Andrea
    Rutter, Martin
    DIABETES, 2015, 64 : A60 - A60
12345